Alzheimer's Drug Increases Toxic Beta Amyloid In Brain, But Still Provides Benefits
Tuesday, July 21, 2009 - 00:28
in Health & Medicine
New insights into how a Phase III Alzheimer's drug might work were among the advances in potential therapies targeting two brain proteins -- amyloid and tau -- recently reported. Scientists also reported on how clinicians view and treat mild cognitive impairment, a research category used to define the state between normal aging and Alzheimer's, that is now being used widely in clinical practice.